Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amishi Y Shah

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Urology|September 5, 2017
Editorial CommentAmishi Y Shah, Nizar M Tannir
International Journal of Dermatology|October 23, 2010
Actinic cheilitis: a treatment reviewAmishi Y Shah, Sean D Doherty, Ted Rosen
Immunotherapy|September 8, 2017
Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancerAmishi Y Shah, Jianjun Gao, Arlene O Siefker-Radtke
Oncology (Williston Park, N.Y.)|February 8, 2019
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerOmar Alhalabi, Amishi Y Shah, Emily A Lemke, et al.
Journal of the Advanced Practitioner in Oncology|December 21, 2020
Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective AnalysisEmily A Lemke, Amishi Y Shah, Matthew Campbell, et al.
Clinical Advances in Hematology & Oncology : H&O|June 8, 2017
Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunitiesGabriel G Malouf, Richard W Joseph, Amishi Y Shah, et al.
Urologic Oncology|June 6, 2017
Optimizing management of upper tract urothelial carcinomaMatthew T Campbell, Amishi Y Shah, Surena F Matin, et al.
Clinical Genitourinary Cancer|May 9, 2018
Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With ChemotherapyKyle Flannery, Xiting Cao, Jinghua He, et al.
Current Opinion in Oncology|April 5, 2021
The evolving treatment landscape of advanced urothelial carcinomaAlexander Y Andreev-Drakhlin, Goar Egoryan, Amishi Y Shah, et al.
Urology Case Reports|June 30, 2015
Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy?Amishi Y Shah, Jose A Karam, Zita D Lim, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Urology|September 5, 2017
Editorial CommentAmishi Y Shah, Nizar M Tannir
International Journal of Dermatology|October 23, 2010
Actinic cheilitis: a treatment reviewAmishi Y Shah, Sean D Doherty, Ted Rosen
Immunotherapy|September 8, 2017
Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancerAmishi Y Shah, Jianjun Gao, Arlene O Siefker-Radtke
Oncology (Williston Park, N.Y.)|February 8, 2019
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerOmar Alhalabi, Amishi Y Shah, Emily A Lemke, et al.
Journal of the Advanced Practitioner in Oncology|December 21, 2020
Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective AnalysisEmily A Lemke, Amishi Y Shah, Matthew Campbell, et al.
Clinical Advances in Hematology & Oncology : H&O|June 8, 2017
Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunitiesGabriel G Malouf, Richard W Joseph, Amishi Y Shah, et al.
Urologic Oncology|June 6, 2017
Optimizing management of upper tract urothelial carcinomaMatthew T Campbell, Amishi Y Shah, Surena F Matin, et al.
Clinical Genitourinary Cancer|May 9, 2018
Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With ChemotherapyKyle Flannery, Xiting Cao, Jinghua He, et al.
Current Opinion in Oncology|April 5, 2021
The evolving treatment landscape of advanced urothelial carcinomaAlexander Y Andreev-Drakhlin, Goar Egoryan, Amishi Y Shah, et al.
Urology Case Reports|June 30, 2015
Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy?Amishi Y Shah, Jose A Karam, Zita D Lim, et al.
Pageof 7